Open an account

Grail

GRAL · NASDAQ

$124.67+$2.25 (+1.84%)TodayMarket closed ·
Prev close $122.42

About GRAL

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 910 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Employees
910
Headquarters
Menlo Park, California
Listed
Jun 12, 2024
Sector
Health Care
Industry
Biotechnology
Website
grail.com

GRAL key statistics

Market cap
5.57B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.38M
Volume
738.86K
Open price
$120.07
High today
$128.52
Low today
$118.66
52 Week high
$166.48
52 Week low
$41.50

Grail (GRAL) at a glance

As of Oct 20, 2026, Grail (GRAL) shares are priced at $124.67, giving the company a market cap of 5.57B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $118.66 and $128.52. The current price is 5.1% above the day's low and 3.0% below its high.

Volume so far is 738.86K shares, below the average of 1.38M shares a day.

Over the past year Grail has ranged from $41.50 to $166.48, and now sits 67% of the way up that range.

Grail met or beat analyst EPS estimates in 7 of the last 7 quarters. In Q2 FY26 it reported -$2.56 per share against an estimate of -$2.71.

The average analyst price target is $99.35, 20.3% below the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 10 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 12 analystsAvg $99.35
Low
$60.60
Now
$124.67
High
$157.50

GRAL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 7 quarters, by 21.2% on average.

  1. Q4 FY24: reported -$2.91 per share against an estimate of -$5.07
  2. Q1 FY25: reported -$3.10 per share against an estimate of -$4.17
  3. Q2 FY25: reported -$3.18 per share against an estimate of -$3.64
  4. Q3 FY25: reported -$2.46 per share against an estimate of -$3.59
  5. Q4 FY25: reported -$2.44 per share against an estimate of -$2.76
  6. Q1 FY26: reported -$2.29 per share against an estimate of -$2.82
  7. Q2 FY26: reported -$2.56 per share against an estimate of -$2.71

GRAL news

  • Press releasePRNewswire

    GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026

  • Vandana Singh

    FDA Panel Endorses GRAIL Galleri Cancer Screening Tool

  • Press releasePRNewswire

    FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test

  • Vandana Singh

    Low False Positives and High Accuracy: FDA Document Fueling Grail Stock Surge

  • Press releasePRNewswire

    GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  • Press releasePRNewswire

    GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference

  • Vandana Singh

    FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test

  • Press releasePRNewswire

    GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

Similar companies

Companies in the same industry as Grail

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.